Inhibition of protein denaturation by fatty acids, bile salts and other natural substances: A new hypothesis for the mechanism of action of fish oil in rheumatic diseases

Japanese Journal of Pharmacology

Volumn 79, Issue 1, 1999, Pages 89-99

  Saso, Luciano ^a   Valentini, Giovanni ^a   Casini, Maria Luisa ^a   Mattei, Eleonora ^a   Braghiroli, Laura ^a   Mazzanti, Gabriela ^a   Panzironi, Claudio ^a   Grippa, Eleonora ^a   Silvestrini, Bruno ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Albumin; Anti rheumatic agent; Antidenaturant agent; Fish oil; n 3 Polyunsaturated fatty acid

Indexed keywords

AMINO ACID; ANTIRHEUMATIC AGENT; ARACHIDONIC ACID; BENDAZAC; BILE ACID CONJUGATE; BILE SALT; BINDARIT; CHENODEOXYCHOLIC ACID; CHOLIC ACID; DECANOIC ACID; DEOXYCHOLIC ACID; DOCOSAHEXAENOIC ACID; FATTY ACID; FISH OIL; GLYCOCHENODEOXYCHOLIC ACID; HUMAN SERUM ALBUMIN; ICOSAPENTAENOIC ACID; INDOMETACIN; INORGANIC SALT; LAURIC ACID; LINOLEIC ACID; LITHOCHOLIC ACID; MYRISTIC ACID; OCTANOIC ACID; OLEIC ACID; OMEGA 3 FATTY ACID; PALMITIC ACID; PHENYLBUTAZONE; STEARIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATTLE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN TISSUE; NONHUMAN; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PROTEIN DENATURATION; PROTEIN STABILITY; RAT; RHEUMATIC DISEASE;

EID: 0032967544     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.79.89     Document Type: Article

References (41)

1. Rose NR: Pathogenic mechanisms in autoimmune diseases. Clin Immunol Immunopathol 53, S7-S16 (1989)
2. Opie EL: On the relation of necrosis and inflammation to denaturation of proteins. J Exp Med 115, 597 (1962)
3. Silvestrini B, Burberi S and Catanese B: Inflammatory responses in normal and adrenalectomized rats during obstructive jaundice. Jpn J Pharmacol 18, 421-429 (1968)
4. Silvestrini B, Natali PG, Catanese B, Barillari G and Cordiali-Fei P: Occurrence of globulin-like migrating blood albumins, or GLIMBAL, in pathological rat and human sera. Can J Biochem 58, 89-92 (1980)
5. Silvestrini B, Guglielmotti A, Saso L and Cheng CY: Changes in concanavalin A-reactive proteins in inflammatory disorders. Clin Chem 35, 2207-2211 (1989)
6. 1-antitrypsin, for diagnostic screening of inflammatory disorders. Clin Chem 36, 277-282 (1990)
7. 1-antitrypsin in diagnostic screening of inflammatory disorders. Int J Immunother 7, 197-204 (1991)
8. 1-antitrypsin in patients with autoimmune diseases. Inflammation 17, 383-400 (1993)
9. 2-macroglobulin, a non-acute-phase protein, in patients with autoimmune diseases. Inflammation 17, 465-479 (1993)
10. Saso L, Silvestrini B, Zwain I, Guglielmotti A, Luparini MR, Cioli V and Cheng CY: Abnormal glycosylation of hemopexin in arthritic rats can be blocked by bindarit. J Rheumatol 19, 1859-1867 (1992)
11. Mizushima Y: Inhibition of protein denaturation by antirheumatic or antiphlogistic agents. Arch Int Pharmacodyn Ther 149, 1-7 (1964)
12. Mizushima Y and Suzuki H: Interaction between plasma proteins and antirheumatic or new antiphlogistic drugs. Arch Intern Pharmacodyn Ther 157, 115-124 (1965)
13. Mizushima Y, Ishii Y and Masumoto S: Physico-chemical properties of potent non-steroidal anti-inflammatory drugs. Biochem Pharmacol 24, 1589-1592 (1975)
14. Grant NH, Alburn HE and Kryzanavskas C: Stabilization of serum albumin by anti-inflammatory drugs. Biochem Pharmacol 19, 715-722 (1970)
15. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 231, 232-235 (1971)
16. Insel PA: Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout. In The Pharmacological Basis of Therapeutics, Edited by Hardman JG, Limbird LE, Molinoff PB, Ruddon RW and Goodman Oilman A, pp 617-657, McGraw Hill, New York (1996)
17. Newbould BB: Suppression of adjuvant induced arthritis in rats with 2-butoxycarbonyl-methylene-4-oxothiazolidine. Br J Pharmacol 24, 632-640 (1965)
18. Silvestrini B: Primary and secondary inflammation. Panminerva Med 11, 587-593 (1969)
19. Silvestrini B, Cioli V and Burberi S: Pharmacological properties of bendazac (AF-983), with particular reference to its topical action on some experimental inflammatory processes. Arzneimittelforschung 19, 30-36 (1969)
20. Silvestrini B, Catanese B, Lisciani R and Alessandroni A: Studies on the mechanism of action of bendazac (AF-983). Arzneimittelforschung 20, 250-253 (1970)
21. Silvestrini B: Rationale for bendazac. In Recent Developments in the Pharmacological Treatment of Cataract, Edited by D'ermo F, Ponte F and Laties AM, pp 1-9, Kugler, Amsterdam (1987)
22. Cioli V, Ciarniello MG, Guglielmotti A, Luparini MR, Durando L, Martinelli B, Catanese B, Fava L and Silvestrini B: A new protein antidenaturant agent, bindarit, reduces secondary phase of adjuvant arthritis in rats. J Rheumatol 19, 1735-1742 (1992)
23. Von Hippel Ph and Wong K: On the conformational stability of globular proteins. J Biol Chem 240, 3909-3923 (1965)
24. Saso L, Valentini G, Panzironi C, Braghiroli L and Silvestrini B: Protective action of some biological agents against albumin heat-induced denaturation. Proceedings of the XXVII Congress of the Italian Society of Pharmacology, held in Turin, Italy, p 591 (1994)
25. Mackay ME and Martin NH: The stabilisation of purified human albumin to heat. Biochem J 65, 284-288 (1957)
26. Peters T: Serum albumin. Adv Protein Chem 37, 161-245 (1985)
27. Hench PS: Potential reversibility of rheumatoid arthritis. Ann Rheum Dis 8, 90 (1949)
28. Hench PS: The effect of jaundice on chronic infections arthritis and on primary fibrositis. Proceedings of the American Rheumatism Association. JAMA 109, 1481 (1937)
29. Kremer JM: Effects of modulation of inflammatory and immune parameters in patients with rheumatic and inflammatory disease receiving dietary supplementation of n-3 and n-6 fatty acids. Lipids 31, S243-S247 (1996)
30. Saso L, Casini ML, Valentini G, Mattei E, Panzironi C and Silvestrini B: Development of an HPLC assay to study the effect of endogenous and exogenous substances on heat-induced aggregation of human serum albumin. Clin Chem Lab Med 36, 155-162 (1998)
31. Tallarida RJ and Murray RB: Manual of Pharmacologic Calculations with Computer Programs. Springer-Verlag, New York (1986)
32. Chen RF: Removal of fatty acids from serum albumin by charcoal treatment. J Biol Chem 242, 173-181 (1967)
33. Roda A, Cappelleri G, Aldini R, Roda E and Barbara L: Quantitative aspects of the interaction of bile acids with human serum albumin. J Lipid Res 23, 490-495 (1982)
34. Ballou GA, Boyer PD, Luck JM and Lum FG: The heat coagulation of human serum albumin. J Biol Chem 153, 589-605 (1944)
35. Boyer PD, Lum FG, Ballou GA, Luck JM and Rice RG: The combination of fatty acids and related compounds with serum albumin. J Biol Chem 162, 181-198 (1946)
36. Lentner C: Geigy Scientific Tables. Vol 3, Medical Education Division, Ciba Geigy Co, West Caldwell, NJ (1984)
37. Kinsella JE: Sources of omega-3 fatty acids in human diets. In Omega-3 Fatty Acids in Health and Disease, Edited by Lees RS and Karel M, p 186, Marcel Dekker, New York (1990)
38. Ishizaka T, Campbell Dh and Ishizaka K: Internal antigenic determinants in protein molecules. Proc Soc Exp Biol Med 103, 5-9 (1960)
39. van Boekel MA, van den Bergh PJ and Hoenders HJ: Glycation of human serum albumin: inhibition by Diclofenac. Biochim Biophys Acta 1120, 201-204 (1992)
40. Kallee E, Eistert U and Wahl R: Inhibitory and disruptive effects of some antirheumatics on antigen-antibody complexes. Eur J Clin Chem Clin Biochem 33, 711-714 (1995)
41. Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, Zalinski J, Cofield M, Mansukhani L, Willson P and Kogan F: Clinical trial of indomethacin in Alzheimer's disease. Neurology 43, 1609-1611 (1993)